Literature DB >> 9099807

A comparison of cathepsin B processing and distribution during neuronal death in rats following global ischemia or decapitation necrosis.

I E Hill1, E Preston, R Monette, J P MacManus.   

Abstract

The objective of this study was to examine the possible role of the cysteine protease cathepsin B (E.C. 3.4.22.1) in the delayed neuronal death in rats subjected to the two-vessel occlusion model of global ischemia. Immunohistochemistry of the hippocampus showed an alteration in the distribution of cathepsin B in CA1 neurons from a lysosomal pattern to a more intense label redistributed into the cytoplasm. This change was not detected until the neurons had become morphologically altered with obvious shrinkage of the cytoplasmic region. Western blotting and enzyme activity measurements of subcellular fractions, including lysosomes and a cell soluble fraction, demonstrated that there was an overall decrease in cathepsin B activity at this time but an increase in the proenzyme form, particularly in the soluble fraction. This was found to be completely different from the marked loss of all forms of cathepsin B in necrotic neurons following decapitation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9099807     DOI: 10.1016/s0006-8993(96)01403-5

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  15 in total

Review 1.  A lysosomal protease enters the death scene.

Authors:  G S Salvesen
Journal:  J Clin Invest       Date:  2001-01       Impact factor: 14.808

2.  An immunohistochemical study on cathepsin D in human hippocampus.

Authors:  M Nogami; A Takatsu; N Endo; I Ishiyama
Journal:  Histochem J       Date:  2000-08

3.  Cathepsin B facilitates autophagy-mediated apoptosis in SPARC overexpressed primitive neuroectodermal tumor cells.

Authors:  P Bhoopathi; C Chetty; M Gujrati; D H Dinh; J S Rao; S Lakka
Journal:  Cell Death Differ       Date:  2010-03-26       Impact factor: 15.828

4.  Improvement in recovery after experimental intracerebral hemorrhage using a selective cathepsin B and L inhibitor.

Authors:  Dongmei Yang; Yuxia Han; Jianfeng Zhang; Christopher Ding; John Anagli; Donald M Seyfried
Journal:  J Neurosurg       Date:  2010-07-30       Impact factor: 5.115

5.  CID1067700, a late endosome GTPase Rab7 receptor antagonist, attenuates brain atrophy, improves neurologic deficits and inhibits reactive astrogliosis in rat ischemic stroke.

Authors:  Yuan Qin; Yang He; Yong-Ming Zhu; Min Li; Yong Ni; Jin Liu; Hui-Ling Zhang
Journal:  Acta Pharmacol Sin       Date:  2018-10-12       Impact factor: 6.150

Review 6.  Molecular pathways in cerebral ischemia: cues to novel therapeutic strategies.

Authors:  Brigitte Onténiente; Sowmyalakshmí Rasika; Alexandra Benchoua; Christelle Guégan
Journal:  Mol Neurobiol       Date:  2003-02       Impact factor: 5.590

Review 7.  Transforming growth factor-beta and ischemic brain injury.

Authors:  Alain Buisson; Sylvain Lesne; Fabian Docagne; Carine Ali; Olivier Nicole; Eric T MacKenzie; Denis Vivien
Journal:  Cell Mol Neurobiol       Date:  2003-10       Impact factor: 5.046

8.  Immunoblot analyses of the relative contributions of cysteine and aspartic proteases to neurofilament breakdown products following experimental brain injury in rats.

Authors:  R M Posmantur; X Zhao; A Kampfl; G L Clifton; R L Hayes
Journal:  Neurochem Res       Date:  1998-10       Impact factor: 3.996

9.  Effects of cathepsins B and L inhibition on postischemic protein alterations in the brain.

Authors:  John Anagli; Kadija Abounit; Paul Stemmer; Yuxia Han; Lisa Allred; Shantel Weinsheimer; Ashkhen Movsisyan; Donald Seyfried
Journal:  Biochem Biophys Res Commun       Date:  2007-12-03       Impact factor: 3.575

10.  The protective effect of dexanabinol (HU-211) on nitric oxide and cysteine protease-mediated neuronal death in focal cerebral ischemia.

Authors:  Ramazan Durmaz; Hilmi Ozden; Güngör Kanbak; Erinç Aral; Okan Can Arslan; Kazim Kartkaya; Kubilay Uzuner
Journal:  Neurochem Res       Date:  2008-04-11       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.